Bo LiangStaff Fellow at FDA/CBERSpeaker
Agenda Sessions
CMC Considerations for Oncolytic Viral Product Development
, 4:30pmView SessionCMC Considerations for Oncolytic Viral Product Development
, 4:30pmView Session